Exhibit 99.1 Company Overview April 2025 NASDAQ: JBIO

Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute forward-looking statements within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade’s ability to achieve the expected benefits or opportunities with respect to JADE-001, JADE-002 and JADE-003, including the expected timelines for JADE-001 entering the clinic and initial data from such trial, the potential of JADE-001, JADE-002 and JADE-003 to become best-in-class drugs and the timing of the combined company’s trading on The Nasdaq Capital Market. The words opportunity, potential, milestones, pipeline, can, goal, strategy, target, anticipate, achieve, believe, contemplate, continue, could, estimate, expect, intends, may, plan, possible, project, should, will, would and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to those uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including its S-4 Registration Statement), as well as risk factors associated with companies, such as Jade, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Market and Industry Data Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications and other data obtained from third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this presentation. Statements as to our market and competitive position data are based on market data currently available to us, as well as management’s internal analyses and assumptions regarding the Company, which involve certain assumptions and estimates. These internal analyses have not been verified by any independent sources and there can be no assurance that the assumptions or estimates are accurate. While we are not aware of any misstatements regarding our industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors. As a result, we cannot guarantee the accuracy or completeness of such information contained in this presentation. 2

Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding through 2027, well-beyond biomarker-rich JADE-001 healthy volunteer data Planned Planned Interim FIH Potential MOA Program Discovery IND-enabling Clinical FIH Data Indications anti-APRIL JADE-001 2H25 1H26 IgAN Multiple Undisclosed JADE-002 1H26 systemic AI diseases Undisclosed JADE-003 1H27 Undisclosed Development candidates licensed from Paragon Assets designed to maximize clinical responses Patient friendly, infrequent dosing Notes: Jade has entered into an exclusive JADE-001 license agreement with Paragon Therapeutics. Jade holds an exclusive option to license JADE-002 and JADE-003 from Paragon. Jade has not yet entered into a license agreement with respect to JADE-002 or JADE-003. 3 MOA – mechanism of action; FIH – First-In-Human; IgAN - IgA nephropathy; AI - autoimmune

JADE-001: a potentially best-in-class anti-APRIL mAb for IgAN 4

Jade is developing a potentially best-in-class anti-APRIL mAb Current treatments Mechanism has Estimated Anti-APRIL do not adequately potential to be disease class poised to be address the need for modifying, reducing $10B+ long-term disease- frontline treatment pathogenic IgA and modifying therapy in branded for IgAN proteinuria, stabilizing a typically young IgAN kidney function market patient population JADE-001 is designed Biomarker-rich and Potentially Efficient to have superior highly translational potency and an HV data expected path to PoC best-in- extended half-life for in 1H26; surrogate maximal efficacy & and market endpoints class convenient dosing expected to support potential profile IgAN approval HV – healthy volunteer, mAb – monoclonal antibody 5 5

~169K+ IgAN patients in the U.S. with majority requiring treatment*, representing potential $10B+ market IgAN patients with persistent proteinuria are ~1M+ global patients, at risk of kidney failure significant potential ex-U.S. market potential IgAN is an autoimmune kidney disease, typically diagnosed 0 100 200 300 400 1,300 US in 20- to 30-year-olds, requiring life-long therapy. ’000 Patients EU Japan China 169 205 103 783 1,260 ~169K+ patients with IgAN in the U.S., with 60-75% requiring treatment per international guidelines There is a high unmet need for disease-modifying treatments that are safe, well-tolerated, and convenient particularly considering that IgAN is often diagnosed in young adults and requires lifelong care *Per KDIGO guidelines, treatment should be initiated in all cases where patients have proteinuria ≥0.5 g/day. Notes: U.S. prevalence estimate from FDA; EU prevalence estimate from EMA; Japan / China prevalence estimates from a Novartis presentation. Estimated pricing of ~$120K-$150K per year based 6 on Filspari and Tarpeyo. Sources: 2023 Pitcher (CJASN); FDA Reviews for Filspari / Tarpeyo; EMA; Novartis; 2018 Schena (Seminars in Nephrology); Reuters IgAN est. prevalence

Proposed updates to KDIGO guidelines support the frontline therapeutic potential of the anti-APRIL class in IgAN Expanding Patient Population IgAN patients at risk of progressive kidney • Kidney biopsy recommended in all adults function loss with proteinuria ≥0.5 g/d where IgAN is a possible diagnosis In all patients these • Recommends additional treatment should Drivers of Manage the generic Manage the IgAN-specific should be addressed response to IgAN-induced nephron be initiated in all cases where patients drivers for nephron loss simultaneously nephron loss loss have proteinuria ≥0.5 g/d Lower Proteinuria Targets • Establishes new treatment goal: proteinuria maintained at <0.5 g/day, preferably <0.3 Reduce pathogenic Reduce glomerular g/day Cardio- forms of IgA and Blood Reduce hyperfiltration and vascular Treatment pressure IgA immune glomerular the impact of risk strategies control complex inflammation proteinuria on the Redefining Treatment Strategies reduction formation tubulointerstitium • New guidelines direct the use of treatments that have been proven to reduce pathogenic forms of IgA KDIGO updates anticipated to increase IgAN diagnosis, expand at-risk patient population requiring treatment, lower proteinuria target to clinical remission, and require targeted therapies that reduce pathogenic IgA. Sources: KDIGO Guidelines Public Review Draft; 2023 Mathur (NEJM); Jade analysis 7 KDIGO – Kidney Disease Improving Global Outcomes

Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach for IgAN Broad B-cell depletion is ineffective in IgAN… …while targeted plasma cell modulation is highly effective. • B-cell depletion with rituximab (anti-CD20) failed to reduce Gd- • APRIL and dual APRIL/BAFF neutralization result in significant and sustained IgA1, anti-Gd-IgA1 autoantibody, or proteinuria and did not depletion of Gd-IgA1, reduction in proteinuria, and eGFR stabilization. impact eGFR. • BAFF neutralization (blisibimod) did not reduce IgA or proteinuria. HIT 1 Plasma cell Mucosa & Production of galactose-deficient Bone marrow Mucosa differentiation bone marrow IgA1 (Gd-IgA1) APRIL blocking HIT 2 therapy Synthesis of anti-Gd-IgA1 autoantibodies HSC Pro B cell Large Small Immature Mature Naïve Plasma cell pre-B cell pre-B cell B cell B cell HIT 3 Autoantibodies bind Gd-IgA1 to form pathogenic immune Memory B cell complexes APRIL CD20 expression HIT 4 Deposition of immune complexes Antibody in the mesangium and initiation of BAFF dependency class-switching kidney injury APRIL dependency *Gradient indicates level of receptor expression Neutralizing APRIL depletes Gd-IgA1, reduces proteinuria, and preserves eGFR, providing a disease-modifying treatment of IgAN without impacting B-cell development and maturation. Sources: 2024 Cheung (Front Nephrol); 2023 Mathur (J Clin Med) 8

Selectively targeting APRIL potentially provides disease modification without added immunosuppression of BAFF inhibition APRIL is the plasma cell survival factor critically linked Targeting APRIL selectively modulates plasma to IgAN pathogenesis and disease activity cells, maintaining pool of mature B cells APRIL BAFF Risk variant in IgAN GWAS ✓✗ Elevated in IgAN patients and associated ✓✓/✗ with disease severity Promotes excess secretion of Gd-IgA1 in IgAN No data ✓ patient lymphocytes ex vivo Drives IgA class switching via TACI in vivo ✓✗ Overexpression in mouse model leads to ✓✓ glomerular IgA deposition KO mouse model decreases IgA levels / IgA+ ✓✗ plasma cells in small intestine Selective inhibition demonstrates preclinical ✓✗ / clinical efficacy in IgAN Existing genomic, mechanistic, IgAN model, and clinical data support the importance of APRIL over BAFF in IgAN, and APRIL-only blockade avoids the potential for unnecessary immunosuppression Sources: 2024 Cheung (Front Nephrol); Chinook 2022 CKD3 Presentation; 2004 Castigli (PNAS); 2001 Schiemann (Science) 9

Reductions in proteinuria and IgA in IgAN clinical studies indicate APRIL inhibition is the driving force behind TACI-Fc efficacy 10 0 Weeks 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -10 Blisibimod (anti-BAFF) -20 Sibeprenlimab (anti-APRIL, 8 mg/kg) Sibeprenlimab (anti-APRIL, 4 mg/kg) -30 Zigakibart (anti-APRIL) -40 Atacicept (TACI-Fc, 150 mg) -50 Atacicept (TACI-Fc, 75 mg) -60 Povetacicept (Eng. TACI-Fc, 240 mg) -70% Povetacicept (Eng. TACI-Fc, 80 mg) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 Weeks -10 -20 -30 TACI-Fc fusion proteins inhibit APRIL & BAFF -40 -50 -60 -70 -80% Notes: Cross-trial comparisons are inherently limited and presented for hypothesis-generating purposes only. Data digitized from graphs where publications did not provide specific values. Values only included if N > 5. Blisibimod W52 data is from W60. 10 Sources: Anthera 2017 10-K; 2023 Mathur (NEJM); 2023 Barratt (ERA Poster); 2024 Lafayette (KI Reports); 2024 Tumlin (WCN Presentation); 2024 Madan (ASN Presentation) IgA 24h UPCR Δ from Baseline (%) Δ from Baseline (%)

No clinical evidence that inhibiting BAFF provides additional efficacy beyond APRIL alone in IgAN Sibeprenlimab Zigakibart Atacicept Povetacicept MoA anti-APRIL anti-APRIL TACI-Fc Engineered TACI-Fc Status P3 P3 P3 P3 IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR Δ from baseline in critical disease markers 33% (W36 timepoint*) 53% 59% 60% 60% 64% 63% 64% 67% 65% 69% 69% N=79 (4/8 mg/kg pooled) N=35 (600 mg) N=32 (150 mg) N=9 (80 mg) ✓✓✓✓ GFR stabilization (12 months) (18 months) (24 months) (12 months) Hematuria No data ✓✓✓ resolution ✓✓✓ ✓ Safety Well tolerated, no overall ↑ infections, Well tolerated (no pbo), no drug Well-tolerated, slight ↑ in infections (& Well-tolerated (no pbo) slight ↑ in URTIs vs. pbo discontinuations URTIs) vs. pbo 240 mg ↑ infections P3 Dosing 400 mg SC, Q4W 600 mg SC, Q2W 150 mg SC, QW 80 mg SC, Q4W Notes: Cross-trial comparisons are inherently limited and presented for hypothesis-generating purposes only. Zigakibart IgA / Gd-IgA data at W40; UPCR data at W52 (only timepoint available); change from baseline is not pbo-controlled; N represents patients on dose(s) for which data is shown. Atacicept infections/URTIs placebo - (32%/0%), 25 mg (38%/0%), 75 mg (49%/9%), 150 mg 11 (39%/6%). Povetacicept infection rates: Grade 1/2/≥3 – 80 mg 10%/5%/0%, 240 mg 18%/27%/3%. Sibeprenlimab infections/URTIs placebo - (55%/0%), 2 mg/kg (39.5%/8%), 4 mg/kg (56%/12%), 8 mg /kg (53%/5%). Sources: 2023 Mathur (NEJM); 2024 Barratt (ERA Presentation); VERA January 2024 R&D Day; ALPN 2024 WCN Investor Update; 2024 Madan (ASN Presentation)

BAFF inhibition is accompanied by the potential for significant long-term B cell depletion Long-term BAFF inhibition significantly depletes … whereas chronic APRIL inhibition does not impact all B cell populations… circulating lymphocytes 9 10 /L ~7-year belimumab data in SLE shows continuous BAFF inhibition lowers B cell populations from ~50% to ~99%, with most populations decreasing >80%. Long-term BAFF suppression, in an otherwise young and healthy patient population, is unnecessary given equivalent efficacy in IgAN from anti-APRILs and TACI-Fcs observed to date. 12 Sources: 2022 Struemper (Lupus Sci Med); Barratt ASN 2024

Deeper APRIL suppression drives superior clinical efficacy • Highest rates of clinical remission (proteinuria <0.3 g/day) for sibeprenlimab was accompanied by the deepest levels of APRIL suppression. • Safety profile consistent across dose levels, with no increase in overall infections. • Potential for anti-APRILs with higher affinity and increased systemic exposure to provide more complete APRIL neutralization throughout the dosing interval and maximize clinical remission rates. Est. P3 AVG equivalent dose JADE-001 has potential to demonstrate (3.5 mg/kg IV) superior clinical activity by maximizing remission rates in significantly more patients than other anti-APRIL programs in development. Proteinuria < 0.3 g/day (% patients @12 mths) Note: Estimated sibeprenlimab P3 dose (400 mg SC) based on average 85 kg IgAN patient (95% CI ~50-120 kg) and 75% bioavailability. 13 Source: 2023 Mathur (NEJM) fAPRIL

Sibeprenlimab is potentially under-dosed in ongoing Phase 3 trial Other anti-APRILs do not inhibit APRIL fully through the dosing interval • Sibeprenlimab dosed as a single 400mg SC injection Q4W in ongoing global Phase 3 VISIONARY trial. • 400 mg SC Q4W equates to ~3.5 mg/kg IV for average Placebo 2 mg/kg IV 4 mg/kg IV 8 mg/kg IV IgAN patient (2.5-6 mg/kg). Annualized eGFR slope 2 (mL/min/1.73m , baseline • Estimated Phase 3 equivalent dose range demonstrated to W52) lower efficacy on key UPCR endpoints in Phase 2 UPCR Δ from ENVISION trial. baseline (%, W36) 0.1 • ~50% of HV in P1 SAD showed positive antidrug antibody 2 mg/kg dose -0.8 activity following single SC dose, which may further did not 13 stabilize eGFR impact PK, efficacy, and safety profile in Phase 3. at 1 year, while higher doses did -4.1 Potential under-dosing of sibeprenlimab 50 -5.9 creates additional opportunity for JADE-001 57 63 to demonstrate potentially best-in-class clinical Est. P3 AVG Est. P3 AVG activity for patients. equivalent dose equivalent dose (3.5 mg/kg IV) (3.5 mg/kg IV) Notes: Estimated sibeprenlimab P3 dose based on average 85 kg IgAN patient (95% CI ~50-120 kg) and 75% bioavailability. Sources: 2023 Mathur (NEJM); 2023 Zhang (Clin Pharm) 14 HV – healthy volunteers; ADA+ – antidrug antibody positive

Potentially best-in-class profile of JADE-001 Femtomolar APRIL Affinity + Half Life Extension Potentially best-in-class Infrequent Q8W+ dosing Avoids unnecessary efficacy immunosuppression Minimizes burden in a typically APRIL inhibitors demonstrate Selectively targeting APRIL provides greater proteinuria reduction and young IgAN patient population disease modifying impact while increased clinical remission rates avoiding B-cell depletion associated potentially requiring life-long therapy with higher exposures and more with BAFF inhibition (≤ 6 injections/year) complete APRIL suppression 15

Potentially best-in-class properties of JADE-001 Ultra-high (fM) APRIL binding Novel IP for composition affinity • Binds APRIL to neutralize activity of matter into mid-2040s • Greater APRIL binding affinity than sibeprenlimab, zigakibart, povetacicept and atacicept De novo antibody discovery Half-life extension through campaign pursued to achieve fully- validated YTE Fc human, potentially best-in-class modification mAb • Longer exposure intended to maximize efficacy and reduce dosing frequency Effector-null human IgG1 Fc Notes; Paragon has filed provisional patent applications covering the subject matter of JADE-001, which we have exclusively licensed from Paragon. No head-to-head clinical trials have been conducted between JADE-001 and the referenced drug candidates. Cross-trial comparisons are inherently limited and presented for hypothesis-generating purposes only. 16 16 fM – femtomolar

JADE-001 has femtomolar affinity and a slow off-rate that is superior to other anti-APRILs currently in development APRIL affinity by SPR is highly predictive of in vivo APRIL affinity by SPR is highly predictive of potency to lower serum IgA in humans in vivo potency to lower serum IgA in humans 1000 Ataci Ziga 100 Sibe 2 R = 0.9987 10 Pove 1 0.1 1 10 100 1000 EC (ηM) 50 Source: Internal data; Benchmarks manufactured based on publicly available sequences. Atacicept APRIL KD 672 pM (Vera internal data). IgA EC estimates calculated using compartmental PK models 50 linked to indirect response models to describe IgA kinetics built using published PK and IgA concentration-time profiles for each molecule. Sibeprenlimab: Mathur, 2022 and Zhang, 2023; Ziga: ASN, 17 2021/2022 and WCN, 2021; Povetacicept: Davies, 2024; Ataci: Willen, 2020, Nestorov, 2008/2010, Munafo, 2007). These data are derived from different trials at different points in time, with differences in trial design and populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials of JADE-001 and other agents have been conducted. KD(pM)

JADE-001 exhibits a highly differentiated NHP PK/PD profile from sibeprenlimab … which is accompanied by deep and prolonged IgA >3X increased half-life compared to sibeprenlimab in NHPs reduction in NHPs following a single, saturating dose coupled with successful mitigation of TMDD … PHARMACOKINETICS PHARMACODYNAMICS JADE-001 (30 mpk) t ~ 27 days 1/2 JADE-001 (4 mpk) Sibeprenlimab (30 mpk) t ~ 7 days 1/2 JADE-001 has the potential to extend dosing interval through low clearance via half-life extension, target-mediated drug disposition mitigation & ultra-high (fM) human affinity. 18 Sibeprenlimab and JADE-001 dosed at 30 mg/kg and 4 mg/kg (single dose), N=4 per group. Comparison agent manufactured based on available sequences from patents / company releases. Study duration shorter for lower dose. ADA+ samples excluded from analysis. Source: Internal data. No head-to-head clinical studies of JADE-001 and other agents have been conducted.

PK, fAPRIL and IgA HV data expected in 1H 2026 Anticipated 1H26 HV data potentially positions and will define the dose and schedule designed to fully suppress fAPRIL throughout the dosing interval JADE-001 for accelerated development in IgAN patients. MOA Program IND Enabling Phase 1 Initiation Interim Healthy Volunteer Data Potential Indications a an nttii--A AP P R RIIL L JADE-001 Ongoing 2H 2025 1H 2026 IgAN • Anti-APRIL MOA provides biomarker rich data predictive Healthy Volunteers (HV) of clinical efficacy • Consistent PK/PD relationships in HV and IgAN patients PK fAPRIL IgA UPCR o HV PK highly predictive of IgAN PK and directly linked to fAPRIL suppression o HV IgA reduction expected to highly correlate with IgAN IgAN Patients IgA reduction o Early IgA response expected to highly correlate with future UPCR reduction in IgAN fAPRIL – Free A Proliferation-Inducing Ligand Sources: Zigakibart: (ASN 2021/2022 and WCN2021). Sibeprenlimab: Mathur 2022 (KI Reports) for Phase 1. Chan 2023 (KI Reports) for Phase 2 IgA; Mathur 2024 (NEJM) for Phase 2 UPCR. Povetacicept: Davies 2024 (Clin Transl Sci) for Phase 1. Madan 2024 (ASN) for Phase 2. Atacicept: Willen 2020 (European Journal of Drug Metabolism and Pharmacokinetics) for Phase 1. Zigakibart: Lo 2020 (ASN) for 19 Phase 1. Barratt 2023 (ERA) for Phase 2 IgA, Barratt 2024 (ASN abstract) for Phase 2 UPCR. Floege 2024 (ERA) for Phase 2. Mezagitamab: December 2024 Takeda SEC from 6-K for Phase 2.

Biomarker-rich, directly translational HV data supports the potential to accelerate clinical development IgA reduction in HVs is highly correlated with IgA …and early IgA reduction further correlates with W36 reduction in IgAN patients at multiple time points… UPCR reduction, the endpoint for accelerated approval Healthy Volunteers vs IgAN Patients IgAN Patients wk4 wk2 wk6 wk4 2 2 wk8 R =0.79 R =0.86 wk2 wk2 wk4 wk4 wk2 wk2 wk4 wk4 wk4 wk4 wk4 wk6 wk6 wk8 wk8 wk8 wk8 HV IgA Δ from baseline (%) IgAN UPCR Δ from baseline (%, W36) Notes: Sibeprenlimab IgAN IgA reductions (LHS) are average of 4 mg/kg and 8 mg/kg cohorts (HV data is from 6 mg/kg cohort); the two cohorts saw effectively equivalent IgA reduction at W4 and W8. Zigakibart UPCR data is at 52W. Atacicept IgAN W8 is average of W4 and W12 datapoints. Trend lines are best linear fit. 20 Sources: 2022 Mathur (KI Reports); 2023 Mathur (NEJM); 2020 Lo (ASN Presentation); 2023 Barratt (ERA Poster); 2024 Barratt (ERA Presentation); 2022 Dillon (ASN Poster); 2024 Tumlin (WCN Presentation); Anthera 2017 10-K; 2024 Lafayette (KI Reports); 2024 Madan (ASN Presentation) IgAN IgA Δ from baseline (%) IgAN IgA Δ from baseline (%, W8)

Pipeline beyond JADE-001 21

Additional Jade programs expected to focus on best-in-class product profiles in high-value autoimmune indications Autoimmune Potentially best- Potential rapid Limited Jade team indications with in-class and path to clinical competition expertise significant best-in- PoC expected market indication opportunity product profile Evaluating additional opportunities to build pipeline of potentially best-in- class autoimmune therapies. 22

Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding through 2027, well-beyond biomarker-rich JADE-001 healthy volunteer data Planned Planned Interim FIH Potential MOA Program Discovery IND-enabling Clinical FIH Data Indications anti-APRIL JADE-001 2H25 1H26 IgAN Multiple Undisclosed JADE-002 1H26 systemic AI diseases Undisclosed JADE-003 1H27 Undisclosed Development candidates licensed from Paragon Assets designed to maximize clinical responses Patient friendly, infrequent dosing Notes: Jade has entered into an exclusive JADE-001 license agreement with Paragon Therapeutics. Jade holds an exclusive option to license JADE-002 and JADE-003 from Paragon. Jade has not yet entered into a license agreement with respect to JADE-002 or JADE-003. 23 MOA – mechanism of action; FIH – First-In-Human; IgAN - IgA nephropathy; AI - autoimmune

Capitalization following close $49.9M cash as of March 31, 2025 of merger with Aerovate +$192.7M net proceeds from PIPE on April 28, 2025 Number of Shares Common stock Shares outstanding 32,235,927 Preferred stock (as converted to 12,622,000 common stock) Common stock equivalents Pre-funded warrants 7,766,247 Common stock & common Total outstanding 52,624,174 stock equivalents Notes: The cash balance figure is preliminary and is subject to change pending completion of our unaudited financial statements for the quarter ended 3/31/25. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of 3/31/25. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this figure and, accordingly, does not express an opinion or any other form of assurance about them. Number of shares are on an as-converted basis and following the 1:35 reverse stock split effected in connection with the merger. The pro forma, post-split fully diluted share count, which includes equity incentives such as employee stock options, is approximately 60.6 million shares. Refer to AVTE and JBIO SEC filings for additional information. 24

Thank you www.JadeBiosciences.com | [email protected] NASDAQ: JBIO